Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF† - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Annals of Oncology Année : 2014

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†

B. Chauffert
H. Taillia
  • Fonction : Auteur
R. Schott
  • Fonction : Auteur
O. Chinot

Dates et versions

hal-01626345 , version 1 (30-10-2017)

Identifiants

Citer

B. Chauffert, L. Feuvret, F. Bonnetain, L. Taillandier, Didier Frappaz, et al.. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. Annals of Oncology, 2014, 25 (7), pp.1442 - 1447. ⟨10.1093/annonc/mdu148⟩. ⟨hal-01626345⟩
61 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More